Onderzoeksgrade Motavizumab

Motavizumab (MEDI-524, NUMAX, NISTmAb) isasecondgenerationmonoclonalantibody (mAb) derivedfrompalivizumab (Synagis) usingaffinitymaturationtechniques.MotavizumabiscurrentlyundergoingUSFoodandDrugAdministrationreviewasatreatmentforrespiratorysyncytialvirus (RSV) prophylaxis.Ithasbeenevaluatedinlarge-scaleclinicalstudies, andhasdemonstratedefficacyinreducingthediseaseburdenofRSVinhigh-riskinfantpopulations.Motavizumab (MEDI-524, NUMAX, NISTmAb) hashigheraffinityandalongerhalf-life, waseffectiveinreducingRSVhospitalizationinhigh-riskfull-terminfantsintheUS, butwasnotlicensedduetosafetyconcerns (allergicreactions) .

MEDI-524, NUMAX, NISTmAb, CR9503, CAS:677010-34-3

Mammalian Cells

F, FusionglycoproteinF0, FusionglycoproteinF2, p27, Interveningsegment, Pep27, Peptide27, FusionglycoproteinF1

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

2.8mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -591°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

HRSV-A

IgG1, kappa